Document is current

Any future updates will be listed below

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer

Crossref DOI link: https://doi.org/10.1038/s41416-025-03092-4

Published Online: 2025-06-20

Published Print: 2025-08-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark